Kintor Pharmaceutical's (HKG:9939) clinical observational study for its KX-826 drug combined with minoxidil for males with androgenetic alopecia in mainland China reached primary endpoints.
The drug company performed the study to improve the design of its phase 3 clinical trial, according to a Friday filing with the Hong Kong bourse.
The study involved two clinical research facilities in China and assessed hair growth and adverse events, among others, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.